Nanoparticle-Based Drug Delivery Systems in Inhaled Therapy: Improving Respiratory Medicine.
Elena CojocaruOvidiu Rusalim PetrișCristian CojocaruPublished in: Pharmaceuticals (Basel, Switzerland) (2024)
Inhaled nanoparticle (NP) therapy poses intricate challenges in clinical and pharmacodynamic realms. Recent strides have revolutionized NP technology by enabling the incorporation of diverse molecules, thus circumventing systemic clearance mechanisms and enhancing drug effectiveness while mitigating systemic side effects. Despite the established success of systemic NP delivery in oncology and other disciplines, the exploration of inhaled NP therapies remains relatively nascent. NPs loaded with bronchodilators or anti-inflammatory agents exhibit promising potential for precise distribution throughout the bronchial tree, offering targeted treatment for respiratory diseases. This article conducts a comprehensive review of NP applications in respiratory medicine, highlighting their merits, ranging from heightened stability to exacting lung-specific delivery. It also explores cutting-edge technologies optimizing NP-loaded aerosol systems, complemented by insights gleaned from clinical trials. Furthermore, the review examines the current challenges and future prospects in NP-based therapies. By synthesizing current data and perspectives, the article underscores the transformative promise of NP-mediated drug delivery in addressing chronic conditions such as chronic obstructive pulmonary disease, a pressing global health concern ranked third in mortality rates. This overview illuminates the evolving landscape of NP inhalation therapies, presenting optimistic avenues for advancing respiratory medicine and improving patient outcomes.
Keyphrases
- drug delivery
- chronic obstructive pulmonary disease
- clinical trial
- global health
- cancer therapy
- cystic fibrosis
- systematic review
- randomized controlled trial
- public health
- anti inflammatory
- emergency department
- palliative care
- big data
- type diabetes
- drug induced
- electronic health record
- stem cells
- bone marrow
- lung function
- coronary artery disease
- artificial intelligence
- drug release
- combination therapy
- adverse drug